Pharmca Proposal to Widen Access and Change the Funded Brand of Hep B and HIV drugs
PHARMAC is proposing the widening of access to tenofovir disoproxil and entecavir, antiviral medicines used for the treatment of hepatitis B and HIV. These changes would have impacts that they would like your feedback on: From 1 June 2018 the Special Authority and Hospital Restrictions for both chemicals would be removed. The funded brand of […]
